Abstract
Frontotemporal lobar degeneration with tau inclusions (FTLD-tau) comprises a class of fatal, heterogeneous neurodegenerative diseases. Approximately 10% of cases arise from pathogenic MAPT mutations, often resulting in severe, early-onset disease with pathology that is distinct yet partially overlapping with sporadic cases. In this study, we evaluated post-mortem tissue from a patient with FTLD-tau due to the MAPT S305I mutation, which presented neuropathology most consistent with argyrophilic grain disease (AGD), a prevalent limbic tauopathy of aging. Structures determined by cryo-electron microscopy (cryo-EM) reveal tau filament folds that differ from those found in sporadic AGD or other tauopathies, featuring a unique four-layer architecture stabilized by the Ile305 substitution within its core. Comparative structural analysis reveals conserved motifs shared among AGD, corticobasal degeneration (CBD), and MAPT P301T. Furthermore, a well-defined density stacks along a cationic cleft, indicative of a bound RNA-like polyanion or small-molecule cofactor. In vitro analysis demonstrates that the S305I mutation promotes fibrillization relative to wild-type tau. These results demonstrate that MAPT S305I stabilizes a distinct aggregation-prone tau fold, contributing to disease heterogeneity beyond known splicing defects, and underscore the potential limitations of using genetic forms as direct models for sporadic FTLD-tau.
Introduction
Tauopathies, including Alzheimer’s disease, corticobasal degeneration (CBD), and argyrophilic grain disease (AGD), are characterized by the pathological aggregation of tau protein. While most instances are sporadic, familial forms caused by mutations in the MAPT gene provide critical insights into disease mechanisms. Historically, because the neuropathology of familial cases often mirrors sporadic ones under light microscopy, researchers have used these mutations to model sporadic disease.
This study investigates the MAPT S305I mutation, which leads to a severe, early-onset frontotemporal dementia. Although the resulting pathology closely resembles sporadic AGD, the underlying molecular architecture remained unknown. Determining whether these similar-looking aggregates share the same 3D structure is vital for ensuring that laboratory models accurately reflect human disease.
Results and Discussion
Cryo-EM Reveals a Novel Four-Layer Fold
Using cryo-electron microscopy and helical reconstruction, we determined the structures of tau filaments extracted from the inferior frontal gyrus of a patient carrying the S305I mutation. We identified two distinct filament types: Type I (comprising ~85% of the population) at 3.1 Å resolution and Type II (~15%) at 3.2 Å resolution.
Both structures feature a novel four-layer architecture that is entirely distinct from the folds observed in sporadic AGD. This finding challenges the assumption that identical-looking pathology implies identical molecular structures. The S305I mutation replaces a polar Serine with a bulky, hydrophobic Isoleucine (Ile). Our structural models show that this Ile305 residue packs perfectly into a hydrophobic pocket within the filament core, providing a stabilizing anchor that wild-type tau cannot replicate. This suggests the mutation itself dictates a unique physical architecture.
Structural Bioinformatics and Conserved Motifs
To compare these new structures against the growing library of tau folds, we employed a novel sliding-window Root Mean Square Deviation (RMSD) algorithm. This analysis allowed for the identification of localized structural motifs rather than just global similarities. Surprisingly, the S305I fold shares more structural motifs with the MAPT P301T mutation and sporadic CBD than it does with sporadic AGD, despite the clinical and pathological similarities to the latter.
The Role of Non-Protein Cofactors
The cryo-EM maps revealed a prominent, unassigned density located within a positively charged (cationic) cleft of the fold. Molecular docking simulations were used to test various candidate molecules. The results suggest that polyanions, such as RNA or polyphosphates, fit the density well. This implies that non-protein cellular cofactors may be essential for nucleating or stabilizing specific toxic tau conformations in vivo.
Intrinsic Aggregation Drive
Previous research suggested that mutations near the S305 position primarily cause disease by disrupting RNA splicing, leading to an imbalance of tau isoforms. However, our in vitro fibrillization assays using Thioflavin T (ThT) fluorescence demonstrated that the S305I mutation directly accelerates the physical aggregation of the protein, with S305I tau clumping nearly twice as fast as wild-type tau. This indicates a dual mechanism of pathogenicity: altered splicing and an intrinsic propensity for the protein to adopt a stable, amyloidogenic fold.
Conclusion
The discovery of the S305I tau fold demonstrates that genetic mutations can drive protein architectures that are distinct from their sporadic counterparts. These findings highlight the complexity of tauopathy heterogeneity and suggest that therapeutic strategies targeting specific tau folds must account for the structural divergence between familial and sporadic disease. Future work will focus on identifying the exact chemical nature of the anionic cofactors and determining how this specific four-layer fold translates into the aggressive clinical progression observed in patients.
Summary updated